Company Profile

Follicum AB is a Sweden-based biopharmaceutical company. The Company develops pharmaceutical treatments to control hair growth. It focuses on both drugs to inhibit and stimulate hair growth. The Company's main drug candidate for hair growth inhibition, FOL-005, is based on an endogenous protein. Its drug candidates for hair growth stimulation, are based on an endogenous protein that is broken down by the body.

Employees

Sector

Biotechnology & Medical Research

More about the company

22-02-06	Coegin Pharma AS completed the acquisition of Follicum AB.	CI
22-02-03	Follicum AB Reports Earnings Results for the Full Year Ended December 31, 2021	CI
21-11-18	Follicum AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-09-22	Coegin Pharma AS agreed to acquire Follicum AB for SEK 35.4 million.	CI
21-08-26	Follicum AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
21-06-24	Follicum AB Reports Revised Top-Line Results from the Phase IIa study of FOL-005 for the Treatment of Hair Loss	CI
21-05-20	Follicum AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021	CI
21-05-10	Follicum AB Announces Executive Changes	CI
21-05-06	Follicum AB Reports Top-Line Results from Phase IIa Study of FOL-005 for Treatment of Hair Loss	CI
21-03-25	Follicum Announces CEO Changes	CI
21-03-25	Follicum AB Establishes New Role as Chief Scientific Officer	CI
21-03-23	Follicum AB Announces New Preclincial Study Confirms Mechanism of Action of its Novel Tissue Repair Peptides	CI
21-02-18	Follicum AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	CI

21-09-23	BioStock: Coegin Pharma fuses with Swedish biotech Follicum	AQ
21-08-30	Follicum : har avslutat sin likviditetsgaranti från Sedermera Fondkommission rörande handeln i aktien	PU
21-06-24	Follicum : reports revised top-line results from the Phase IIa study of FOL-005 for the treatment of hair loss (alopecia)	AQ
21-06-03	BioStock article: Hopeful stock surge in Follicum after suspected analysis error in hair loss project	PU
21-06-03	BioStock: Hopeful stock surge in Follicum after suspected analysis error in hair loss project	AQ

Director	Title	Age	Since
Lars Henrik Bruzelius BRD	Director/Board Member	83	2012-12-31
Gun-Britt Fransson CHM	Chairman	73	2017-12-31
Alejandra Maria Mørk BRD	Director/Board Member	65	2017-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOLLICUM AB (PUBL)	+4.72%	+12.34%	-	-	3.15M
LONZA GROUP AG	+2.37%	+0.66%	+4.21%	+22.74%	48.63B
REVOLUTION MEDICINES, INC.	-0.62%	+4.43%	+488.92%	+624.71%	46.3B
BEONE MEDICINES AG	+2.09%	+4.90%	+18.02%	+95.21%	41.97B
IQVIA HOLDINGS INC.	+3.85%	+2.23%	+29.47%	+16.50%	39.51B
CELLTRION, INC.	-0.72%	-7.79%	+17.87%	+47.98%	31.75B
MEDPACE HOLDINGS, INC.	+3.04%	+0.46%	+31.40%	+143.62%	16.48B
ASCENDIS PHARMA A/S	+4.33%	+1.98%	-	-	16.34B
EUROFINS SCIENTIFIC SE	+1.44%	+1.09%	+4.93%	+31.00%	14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+3.87%	+2.84%	+84.74%	+45.80%	13.33B
Average	+2.44%	-0.60%	+84.94%	+128.44%	29.81B
Weighted average by Cap.	+1.85%	-0.05%	+107.33%	+157.21%

Follicum AB (publ) Stock

Stocks

FOLLI

SE0006288270

Biotechnology & Medical Research

Latest news : Follicum AB (publ)

Press Releases: Follicum AB (publ)

Quotes and Performance

Managers and Directors: Follicum AB (publ)

Other Biotechnology & Medical Research

Company Profile